Table 1.
Clinical and biochemical characteristics of the study population.
| Controls | Patients with T2DM | Patients with CHD | |
|---|---|---|---|
| n | 30 | 25 | 25 |
| Age (years) | 61.3 ± 7.7 | 63.3 ± 9.2 | 66.2 ± 10.8 |
| Gender (M/F) | 17/13 | 15/10 | 20/5 |
| Hypertension (n) | 6 | 11 | 15 |
| Body Mass Index (Kg/m2) | 26.5 ± 1.2 | 27.2 ± 2.1 | 26.2 ± 4.2 |
| Current Smokers (n) | 6 | 6 | 11 |
| Metabolic syndrome (n) | 7 | 23 § | 16 § # |
| Number of metabolic syndrome criteria (n) | 2.1 ± 0.9 | 3.1 ± 0.5 † | 3 ± 1.1 † |
| Family history of premature CVD (n) | 2 | 1 | 7 |
| Total cholesterol (mg/dL) | 192.4 ± 41.6 | 215.0 ± 45.0 | 189.7 ± 34.3 |
| Triglycerides (mg/dL) | 114.7 ± 40.9 | 122.2 ± 43.5 | 137.8 ± 45.7 |
| HDL-Cholesterol (mg/dL) | 44.9 ± 9.3 | 48.4 ± 10.0 | 42.8 ± 6.6 |
| LDL-Cholesterol (mg/dL) | 124.5 ± 35.3 | 142.1 ± 40.0 | 119.3 ± 29.1 |
| non-HDL-Cholesterol (mg/dL) | 147.5 ± 38.9 | 166.6 ± 38.6 | 146.9 ± 32.3 |
| Apolipoprotein AI (mg/dL) | 131.1 ± 23.5 | 136.5 ± 21.0 | 121.5 ± 21.5 |
| Apolipoprotein B (mg/dL) | 91.0 ± 23.4 | 99.5 ± 20.9 | 91.4 ± 24.3 |
| Fasting glucose (mg/dL) | 93.9 ± 8.7 | 151.8 ± 25.4 * | 99.4 ± 11.9 |
| HbA1c (%) | 4.7 ± 0.6 | 7.3 ± 0.5 * | 5.0 ± 0.4 |
Entries are mean ± SD, CHD = coronary heart disease; § p < 0.05 and # p < 0.05 vs. control and type-2 diabetes mellitus group, respectively (by Yates-corrected x2 test); † p < 0.01 vs. control group; * p < 0.001 vs. control and CHD groups.